



Colorado Multiple Institutional Review Board, CB
F490
University of Colorado, Anschutz Medical Campus
13001 E. 17th Place, Building 500, Room N3214
Aurora, Colorado 80045

303.724.1055 [Phone]
303.724.0990 [Fax]
[COMIRB Home Page](#) [Web]
comirb@ucdenver.edu [E-Mail]
FWA00005070 [FWA]

University of Colorado Hospital
Denver Health Medical Center
Veteran's Administration Medical Center
Children's Hospital Colorado
University of Colorado Denver
Colorado Prevention Center

Certificate of Approval

This study has been reviewed and meets the criteria for COMIRB approval. This study involves the VAMC and VA R&D Committee approval is PENDING. **Research activities involving the VAMC, including any activities on a VA-only study, can only take place with VA R&D Committee approval.**

28-Jan-2017

Investigator: Liron Caplan
Subject: COMIRB Protocol 06-0956 Continuing Review
Review Date: 24-Jan-2017
Effective Date: 24-Jan-2017
Expiration Date: 23-Jan-2018
Sponsor(s):
Title: VETERANS AFFAIRS RHEUMATOID ARTHRITIS (VARA) REGISTRY

Submission ID: CRV010-1

SUBMISSION DESCRIPTION:

Study Status: Enrollment Continues

Submitted concurrently with PAM013-1

Your COMIRB Continuing Review submission CRV010-1 has been APPROVED until the expiration date listed above. The investigator will need to submit this research for Continuing Review at least 45 days prior to the expiration date.

Study personnel are approved to conduct the research as described in the documents approved by COMIRB, which are listed below the REVIEW DETAILS section.

Please carefully review the REVIEW DETAILS section because COMIRB may have made red-line changes (i.e. revisions) to

the submitted documents prior to approving them. The investigator can submit an amendment to revise the documents if the investigator does not agree with the red-line changes. The REVIEW DETAILS section may also include important information from the reviewer(s) and COMIRB staff.

COMIRB stamps the approved versions of documents in the top right hand corner. Stamped copies of documents are available for download through COMIRB's electronic submission website, eRA(InfoEd).

[Click here for instructions on how to retrieve stamped documents.](#)

REVIEW DETAILS:

+++++

PLEASE NOTE: The following study staff are not eligible to participate in this study until they have become compliant with the COMIRB Requirements for research staff:

1. Phat Luong (CITI Group 1 HS Course expired 12/13/2016 - the Refresher course is needed)

+++++

At your next Continuing Review, please check your response to CR Form Q13a to make sure the number of VA enrollees matches the data in Table 1 and please update your HIPAA B form to the current VA HIPAA form.

+++++

The following documents have been reviewed by the Chair and stamped APPROVED or NOTED as part of this approval:

PDF CR Form
CoverLetter_CR_ 1232017
Adverse Event Summary_CR_2017
Application with Attachments A, F, M, O, P, Q, R, S, S1, v 01.7.16
Description of withdrawals_CR_2017
Personnel Form (eForm) v 12.02.16
Protocol_v8_05.29.15
VA Informed Consent Form v 05.22.2015
VA SRS Form – (no date)

Continuing Review **CRV010-1** was reviewed and approved concurrently with Amendment **PAM013-1**. Some documents submitted as part of the Continuing Review were not stamped approved due to new versions of those documents being approved as part of the Amendment. It is noted that the stamped version of the previously approved documents are already on file with COMIRB.

If this protocol requires full-board review and includes attachment C and/or D, the PI will be required to complete GCP training.

COMIRB will begin enforcing this new requirement on 9/1/15. It is highly recommended that you complete this training as soon as possible to prevent delays on approvals after the 9/1/15 deadline.

For the duration of this research the investigator must:

- Submit any change in the research design, personnel, and any new or changed study documents (including new/changed consent forms, questionnaires, advertisements, ect.) to COMIRB and receive approval before implementing the changes.
- Use only a copy of the COMIRB-approved, stamped Consent and/or Assent Form. The investigator bears the responsibility for obtaining from all subjects "Informed Consent" as required by COMIRB. COMIRB REQUIRES that the subject be given a copy of the consent and/or assent form after it is signed.
- Provide non-English speaking subjects with a certified translation of the approved Consent and/or Assent Form in the subject's first language or use a Consent Short Form, as approved for the study.
- Inform COMIRB immediately of any Unanticipated Problems that are unexpected and related to the study in accordance with COMIRB Policies and Procedures.
- Maintain approval for the research. COMIRB approval is generally given in one year increments, but the period may be shorter. Research is required to be submitted for continuing review and re-approval at least 45 days prior to the expiration date. If a study's approval expires, investigators must stop all research activities immediately (including data analysis) and contact the COMIRB office for guidance.
- Remain actively engaged in the conduct of the research. The investigator must ensure that all enrolled participants are appropriate for the study prior to study procedures beginning. For FDA-regulated research the investigator must sign the investigator line on the consent form prior to participants receiving study-related interventions.

Information on how to submit changes (amendments) to your study, requests for continuing review, and reports of unanticipated problems to COMIRB can be found on the COMIRB website <http://www.ucdenver.edu/research/comirb/training/>.

Contact COMIRB with questions at 303-724-1055 or COMIRB@ucdenver.edu.

As part of this review it was determined that for this research:

1. Risks to subjects are minimized.
2. Risks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the importance of the knowledge that may reasonably be expected to result.
3. Selection of subjects is equitable.
4. Informed consent will be sought from each prospective subject or the subject's legally authorized representative in accordance with, and to the extent required by, §46.116.
5. Informed consent will be appropriately documented in accordance with, and to the extent required by, §46.117.
6. The research plan makes adequate provision for monitoring the data collected to ensure the safety of subjects.
7. There are adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data.
8. Appropriate safeguards are in place to protect potentially vulnerable populations from coercion and undue influence.

Sincerely,

UCD Panel A

